Founded with a mission to revolutionize the treatment of autoimmune diseases, Landos Biopharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class oral therapeutics. The company's core vision is to provide innovative, effective, and accessible treatments for patients suffering from conditions such as ulcerative colitis and Crohn’s disease. Their leading product, NX-, is an oral NLRX1 agonist designed to reduce reactive oxygen species and oxidative stress while minimizing pro-inflammatory signals.
Landos Biopharma has attracted notable investors and scientific minds committed to advancing autoimmune disease treatments. The company has achieved significant milestones in clinical trials, demonstrating promising results for its flagship product, NX-. By focusing on novel pathways at the interface of immunity and metabolism, Landos Biopharma aims to make a substantial impact on the quality of life for patients with autoimmune disorders, positioning itself as a leader in the biopharmaceutical industry.
